TET2突变巨细胞动脉炎患者具有更高风险特征:一项聚类分析
在三家医院的前瞻性观察研究中,49例巨细胞动脉炎(GCA)患者、48例其他自身免疫病(AID)患者和27名对照者的克隆性造血(CH)检出率分别为55.1%、18.8%和59.3%,校正年龄和性别后GCA与对照或其他AID间无显著差异。聚类分析在GCA患者中识别出两个不同组群,其中一组TET2和JAK2变异患病率更高且与更差预后相关。
要点
- GCA患者CH检出率为55.1%,对照为59.3%,其他AID为18.8%,校正年龄和性别后无显著差异。
- GCA和对照组中最常见的突变基因为DNMT3A和TET2。
- 聚类分析显示GCA中存在TET2和JAK2变异患病率更高且预后更差的组群。
核心结论
- CH在GCA患者中常见,但与对照或其他自身免疫病相比无显著差异。
- 特定遗传特征,特别是TET2和JAK2突变,与GCA队列中更高风险的组群相关。
- 作者认为这一观察突显了在常规实践和临床试验中检测GCA患者CH以进行更好风险分层的意义。
- 作者指出需要进一步的前瞻性研究来确定根据遗传特征定制管理是否能改善结局。
研究设计与样本
- 前瞻性观察研究,在三家医院纳入49例诊断为GCA的患者、48例其他AID患者和27名对照参与者。
- 采用下一代测序检测克隆性造血。
主要发现
- CH在GCA患者中检出率为55.1%,对照为59.3%,其他AID患者为18.8%。
- GCA和对照组中最常见的突变基因为DNMT3A和TET2。
- 校正年龄和性别后,GCA与对照或其他AID之间CH患病率无显著差异。
- 聚类分析在GCA患者中揭示两个不同组群,其中一组TET2和JAK2变异患病率更高,且与更差预后相关。
临床怎么用
- 作者认为在常规实践和临床试验中检测GCA患者CH有助于更好风险分层。
- 作者指出需要进一步前瞻性研究确定根据遗传特征定制管理是否能改善结局。
局限性
- 需要进一步的前瞻性研究来确定根据遗传特征定制管理是否能改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to assess the prevalence of clonal haematopoiesis (CH) in patients with giant cell arteritis (GCA) compared with controls and individuals with other autoimmune diseases (AIDs) and to identify high-risk clinical/genetic profiles that could influence disease outcomes. METHODS: In a prospective observational study at three hospitals, we included 49 patients diagnosed with GCA, 48 patients with other AIDs and 27 control participants. We used next-generation sequencing to detect clonal haematopoiesis (CH) among them. RESULTS: CH was detected in 55.1% of patients with GCA, 59.3% of controls and 18.8% of patients with other AIDs. The most commonly mutated genes in GCA and control groups were DNMT3A and TET2. No significant differences in CH prevalence were found between patients with GCA and controls or other AID when adjusted for age and sex. Cluster analysis revealed two distinct groups within the patients with GCA, one of which displayed a higher prevalence of TET2 and JAK2 variants, and was associated with worse prognosis. CONCLUSIONS: CH is prevalent among patients with GCA but does not differ significantly from controls or other autoimmune conditions. However, specific genetic profiles, particularly mutations in TET2 and JAK2, are associated with a higher risk cluster within the GCA cohort. This observation highlights the interest of detecting CH in patients with GCA in both routine practice and clinical trials for better risk stratification. Further prospective studies are needed to determine if management tailored to the genetic profile would improve outcomes.
引用
- Guedon AF, Ouafdi A, Belfeki N, et al. Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis. RMD Open. 2024. PMID: 39658053. doi:10.1136/rmdopen-2024-004694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。